FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106428113> ?p ?o ?g. }

• W2106428113 endingPage "2598" @default.
• W2106428113 startingPage "2593" @default.
• W2106428113 abstract "No AccessJournal of UrologyPediatric urololgy1 Dec 2007Botulinum-A Toxin: Solo Treatment for Neuropathic Noncompliant Bladder Khalid Fouda Neel, Sherif Soliman, Mahmoud Salem, Mohammed Seida, Hamdan Al-Hazmi, and Amenah Khatab Khalid Fouda NeelKhalid Fouda Neel More articles by this author , Sherif SolimanSherif Soliman More articles by this author , Mahmoud SalemMahmoud Salem More articles by this author , Mohammed SeidaMohammed Seida More articles by this author , Hamdan Al-HazmiHamdan Al-Hazmi More articles by this author , and Amenah KhatabAmenah Khatab More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2007.08.032AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We investigated whether botulinum-A toxin is better used alone or in conjunction with oxybutynin chloride in the management of refractory neuropathic bladder. Materials and Methods: Between March 2004 and February 2006 a total of 23 children (mean age 5.6 ± 2.5 years) with neuropathic bladder refractory to medical treatment underwent cystoscopic treatment with botulinum-A toxin. Patients were randomly assigned postoperatively using closed envelopes (blind randomization) into 2 equal groups. Group 1 (12 patients) continued to receive anticholinergics while in group 2 (11 patients) anticholinergics were discontinued. Clinical and urodynamic evaluations were performed before injection, and at 1 and 6-month intervals. Patients were then followed every 6 months with urodynamic study. The outcomes were compared between groups with a paired t test (2-tailed) and a significant p value <0.025. Results: Maximum bladder capacity increased from 96 ± 67 (range 15 to 277) to 163 ± 96 ml (range 50 to 500, p <0.001) and 142 ± 65 ml (range 21 to 250, p <0.006) at 1 and 6 months, respectively. Maximal detrusor pressure decreased from 76 ± 36 (range 36 to 209) to 50 ± 22 cm H2O (range 20 to 100, p <0.001) and 51 ± 21 cm H2O (range 18 to 104, p <0.001) at 1 and 6 months, respectively. From a clinical point of view 9 of the 16 incontinent patients (56.2%) showed complete continence after treatment while 4 (25%) reported mild to moderate improvement and 3 (18.8%) showed no improvement. None of the patients had side effects related to the procedure or the material used. Conclusions: We confirmed the beneficial use of botulinum-A toxin for the treatment of refractory neuropathic bladder and have not yet found any augmentative effect of oxybutynin chloride in this study group. Accordingly we can use such a modality as sole treatment for noncompliant neuropathic bladder. References 1 : Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol2003; 44: 165. Google Scholar 2 : Pharmacology and immunology of botulinum toxin serotypes. J Neurol2001; 248: 3. Google Scholar 3 : Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med1997; 40: 317. Google Scholar 4 : Pharmacologic weakening of extraocular muscles. Invest Ophthalmol1973; 12: 924. Google Scholar 5 : Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc1981; 79: 734. Google Scholar 6 : Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol1988; 139: 919. Link, Google Scholar 7 : Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int2006; 98: 1033. Google Scholar 8 : Botulinum toxin A in management of cerebral palsy. Pediatr Neurol1994; 10: 284. Google Scholar 9 : Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol1994; 152: 1582. Link, Google Scholar 10 : Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology2002; 59: 325. Google Scholar 11 : Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol2003; 44: 139. Google Scholar 12 : Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol2004; 171: 845. Link, Google Scholar 13 : Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology2006; 68: 1091. Google Scholar 14 : Prognostic value of urodynamic testing in myelodysplastic patients. J Urol1981; 126: 205. Link, Google Scholar 15 : Predictive value of urodynamic evaluation in newborns with myelodysplasia. JAMA1984; 252: 650. Google Scholar 16 : Long-term evaluation of metabolic profile and bone mineral density after ileocystoplasty in children. J Urol2003; 170: 1639. Link, Google Scholar 17 : Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol1997; 157: 638. Link, Google Scholar 18 : European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol2004; 45: 510. Google Scholar Pediatric Urological Service, Pediatric Urodynamic (MS) and Pediatric Urotherapy (AK) Units, Department of Surgery, King Khalid University Hospital, Riyadh, Saudi Arabia© 2007 by American Urological AssociationFiguresReferencesRelatedDetailsCited byHarper L (2018) Botulinum Toxin A—When is a Unit Not a Unit?Journal of Urology, VOL. 181, NO. 1, (414-415), Online publication date: 1-Jan-2009. Volume 178Issue 6December 2007Page: 2593-2598 Advertisement Copyright & Permissions© 2007 by American Urological AssociationKeywordsneurogenicbotulinum toxin type Aurinary bladderMetricsAuthor Information Khalid Fouda Neel More articles by this author Sherif Soliman More articles by this author Mahmoud Salem More articles by this author Mohammed Seida More articles by this author Hamdan Al-Hazmi More articles by this author Amenah Khatab More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2106428113 created "2016-06-24" @default.
• W2106428113 creator A5013200465 @default.
• W2106428113 creator A5013366982 @default.
• W2106428113 creator A5040129626 @default.
• W2106428113 creator A5066281134 @default.
• W2106428113 creator A5074221210 @default.
• W2106428113 creator A5076629148 @default.
• W2106428113 date "2007-12-01" @default.
• W2106428113 modified "2023-09-26" @default.
• W2106428113 title "Botulinum-A Toxin: Solo Treatment for Neuropathic Noncompliant Bladder" @default.
• W2106428113 cites W1257881779 @default.
• W2106428113 cites W1966558756 @default.
• W2106428113 cites W1990227511 @default.
• W2106428113 cites W1995794076 @default.
• W2106428113 cites W2011978617 @default.
• W2106428113 cites W2026299491 @default.
• W2106428113 cites W2036787880 @default.
• W2106428113 cites W2058300311 @default.
• W2106428113 cites W2077298856 @default.
• W2106428113 cites W2087154837 @default.
• W2106428113 cites W2116496261 @default.
• W2106428113 cites W2163507633 @default.
• W2106428113 cites W2167935693 @default.
• W2106428113 cites W2417754135 @default.
• W2106428113 cites W4240783537 @default.
• W2106428113 cites W4256631357 @default.
• W2106428113 doi "https://doi.org/10.1016/j.juro.2007.08.032" @default.
• W2106428113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17945300" @default.
• W2106428113 hasPublicationYear "2007" @default.
• W2106428113 type Work @default.
• W2106428113 sameAs 2106428113 @default.
• W2106428113 citedByCount "34" @default.
• W2106428113 countsByYear W21064281132012 @default.
• W2106428113 countsByYear W21064281132013 @default.
• W2106428113 countsByYear W21064281132014 @default.
• W2106428113 countsByYear W21064281132015 @default.
• W2106428113 countsByYear W21064281132016 @default.
• W2106428113 countsByYear W21064281132017 @default.
• W2106428113 countsByYear W21064281132019 @default.
• W2106428113 countsByYear W21064281132020 @default.
• W2106428113 countsByYear W21064281132021 @default.
• W2106428113 countsByYear W21064281132023 @default.
• W2106428113 crossrefType "journal-article" @default.
• W2106428113 hasAuthorship W2106428113A5013200465 @default.
• W2106428113 hasAuthorship W2106428113A5013366982 @default.
• W2106428113 hasAuthorship W2106428113A5040129626 @default.
• W2106428113 hasAuthorship W2106428113A5066281134 @default.
• W2106428113 hasAuthorship W2106428113A5074221210 @default.
• W2106428113 hasAuthorship W2106428113A5076629148 @default.
• W2106428113 hasConcept C121332964 @default.
• W2106428113 hasConcept C126894567 @default.
• W2106428113 hasConcept C142424586 @default.
• W2106428113 hasConcept C71924100 @default.
• W2106428113 hasConcept C87355193 @default.
• W2106428113 hasConceptScore W2106428113C121332964 @default.
• W2106428113 hasConceptScore W2106428113C126894567 @default.
• W2106428113 hasConceptScore W2106428113C142424586 @default.
• W2106428113 hasConceptScore W2106428113C71924100 @default.
• W2106428113 hasConceptScore W2106428113C87355193 @default.
• W2106428113 hasIssue "6" @default.
• W2106428113 hasLocation W21064281131 @default.
• W2106428113 hasLocation W21064281132 @default.
• W2106428113 hasOpenAccess W2106428113 @default.
• W2106428113 hasPrimaryLocation W21064281131 @default.
• W2106428113 hasRelatedWork W2068316626 @default.
• W2106428113 hasRelatedWork W2110818089 @default.
• W2106428113 hasRelatedWork W2351796763 @default.
• W2106428113 hasRelatedWork W2351985199 @default.
• W2106428113 hasRelatedWork W2392413698 @default.
• W2106428113 hasRelatedWork W2403502999 @default.
• W2106428113 hasRelatedWork W2567738959 @default.
• W2106428113 hasRelatedWork W2923882796 @default.
• W2106428113 hasRelatedWork W4297834875 @default.
• W2106428113 hasRelatedWork W4366141624 @default.
• W2106428113 hasVolume "178" @default.
• W2106428113 isParatext "false" @default.
• W2106428113 isRetracted "false" @default.
• W2106428113 magId "2106428113" @default.
• W2106428113 workType "article" @default.